SCHEMBL958258

SCHEMBL958258

COc1ccc(-c2ccc(S(N)(=O)=O)cc2C)cn1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
KCNH2 Q12809 4/20 0.55
CYP2A6 P11509 1/20 0.49
PTGS2 P35354 1/20 0.47
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
PTGES2 Q9H7Z7 1/20 0.45
OXTR P30559 4/20 0.44
AVPR2 P30518 1/20 0.44
AVPR1A P37288 1/20 0.44
NNMT P40261 1/20 0.44
LRRK2 Q5S007 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
ERN1 O75460 1/20 0.43
PIK3CA P42336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL958145 0.81 KCNH2 (0.47) CA1CA2KCNH2CYP2A6PTGES2
SCHEMBL1422276 0.81 CA2 (0.72) CA1CA2KCNH2CYP2A6PTGS2
SCHEMBL957121 0.81 PTGS2 (0.56) CA1CA2CYP2A6PTGS2CA12
SCHEMBL2224383 0.79 KCNH2 (0.81) CA1CA2KCNH2PIK3CA
SCHEMBL6050697 0.78 CA1 (0.64) CA1CA2KCNH2CYP2A6PTGS2
SCHEMBL6050725 0.78 CA1 (0.61) CA1CA2KCNH2CYP2A6PTGS2
SCHEMBL1422284 0.77 CA1 (0.61) CA1CA2KCNH2PTGS2MKNK1
SCHEMBL28819367 0.77 CA1 (0.61) CA1CA2KCNH2PTGS2MKNK1
SCHEMBL15959127 0.77 HSD17B1 (0.59) CYP2A6MKNK1MKNK2NNMTERN1
Hydrochloric Acid SCHEMBL29969325 0.76 CA1 (0.60) CA1CA2KCNH2PTGS2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US disclosed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP disclosed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents FBP1, PFKFB1, PFKFB3 CA1 2473/4885CA2 506/4885KCNH2 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.